EGRX Stock EGRX is expected to report earnings to fall -1.83% to $1.07 per share on February 28

A.I.dvisor
at Tickeron.com
05/12/24
Loading...
EGRX - Eagle Pharmaceuticals
Eagle Pharmaceuticals Earnings Graph
Q4'23
Est.
$1.07
Q3'23
Est.
$1.09
Q2'23
Beat
by $0.11
Q1'23
Beat
by $0.33
Q4'22
Beat
by $0.28
The last earnings report on September 30 showed earnings per share of $1.09, meeting the estimate of $1.09. P/B Ratio (0.246) is normal, around the industry mean (49.719). P/E Ratio (5.635) is within average values for comparable stocks, (83.200). EGRX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.825). Dividend Yield (0.000) settles around the average of (0.115) among similar stocks. P/S Ratio (0.245) is also within normal values, averaging (62.541). With 122.64K shares outstanding, the current market capitalization sits at 62.07M.
View a ticker or compare two or three
EGRXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of pharmaceutical preparations

Industry PharmaceuticalsOther

Profile
Fundamentals
Details
Industry
Pharmaceuticals Other
Address
50 Tice Boulevard
Phone
+1 201 326-5300
Employees
134
Web
http://www.eagleus.com